Patents by Inventor Akiko Egami

Akiko Egami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES
    Publication number: 20230025510
    Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof having an inhibitory action on an EGFR tyrosine kinase having an exon 20 insertion mutation and/or a HER2 tyrosine kinase having an exon 20 insertion mutation, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5 and R6 in the Formula (I) are each as defined in the description.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 26, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenichi Yoshida, Kosuke Takeuchi, Hidekazu Inoue, Hideaki Kageji, Takayuki Momose, Keisuke Yoshida, Takeshi Jimbo, Akiko Egami
  • EP300/CREBBP inhibitor
    Patent number: 11274100
    Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: March 15, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroyuki Naito, Yoshiko Kagoshima, Hideaki Funami, Akifumi Nakamura, Masayoshi Asano, Makoto Haruta, Takashi Suzuki, Jun Watanabe, Ryutaro Kanada, Saito Higuchi, Kentaro Ito, Akiko Egami, Katsuhiro Kobayashi
  • EP300/CREBBP INHIBITOR
    Publication number: 20210171520
    Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.
    Type: Application
    Filed: June 21, 2018
    Publication date: June 10, 2021
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroyuki Naito, Yoshiko Kagoshima, Hideaki Funami, Akifumi Nakamura, Masayoshi Asano, Makoto Haruta, Takashi Suzuki, Jun Watanabe, Ryutaro Kanada, Saito Higuchi, Kentaro Ito, Akiko Egami, Katsuhiro Kobayashi